{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sweeney N"],"funding":["Guy's and St Thomas' Charity","King's Together Rapid COVID-19 call","NIAID NIH HHS","Medical Research Council","National Institute for Health Research (NIHR)","King's Together Rapid COVID-19 Call","Fondation Dormeur","Wellcome Trust"],"pagination":["e0249791"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8026061"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(4)"],"pubmed_abstract":["During the first wave of the global COVID-19 pandemic the clinical utility and indications for SARS-CoV-2 serological testing were not clearly defined. The urgency to deploy serological assays required rapid evaluation of their performance characteristics. We undertook an internal validation of a CE marked lateral flow immunoassay (LFIA) (SureScreen Diagnostics) using serum from SARS-CoV-2 RNA positive individuals and pre-pandemic samples. This was followed by the delivery of a same-day named patient SARS-CoV-2 serology service using LFIA on vetted referrals at central London teaching hospital with clinical interpretation of result provided to the direct care team. Assay performance, source and nature of referrals, feasibility and clinical utility of the service, particularly benefit in cl"],"journal":["PloS one"],"pubmed_title":["Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection syndromes: Results from a pilot service implemented during the first pandemic wave."],"pmcid":["PMC8026061"],"funding_grant_id":["HHSN272201400008C","WT098049AIA","ACF-2019-17-014","MR/S023747/1","207442/Z/17/Z","MR/R015643/1","RJ112/N027","MC/PC/15068","106223/Z/14/Z","MR/N013700/1"],"pubmed_authors":["Botgros A","Seow J","Pickering S","Tan MKI","Malim MH","Sweeney N","Doores K","MacMahon E","Graham C","Kouphou N","Merrick B","Signell AW","Wilson HD","Batra R","Ramble J","Nebbia G","Douthwaite S","Acors S","Edgeworth JD","Neil SJD","Pedro Galao R","Betancor G"],"additional_accession":[]},"is_claimable":false,"name":"Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection syndromes: Results from a pilot service implemented during the first pandemic wave.","description":"During the first wave of the global COVID-19 pandemic the clinical utility and indications for SARS-CoV-2 serological testing were not clearly defined. The urgency to deploy serological assays required rapid evaluation of their performance characteristics. We undertook an internal validation of a CE marked lateral flow immunoassay (LFIA) (SureScreen Diagnostics) using serum from SARS-CoV-2 RNA positive individuals and pre-pandemic samples. This was followed by the delivery of a same-day named patient SARS-CoV-2 serology service using LFIA on vetted referrals at central London teaching hospital with clinical interpretation of result provided to the direct care team. Assay performance, source and nature of referrals, feasibility and clinical utility of the service, particularly benefit in cl","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2026-06-04T03:06:45.042Z","creation":"2022-02-09T15:35:17.689Z"},"accession":"S-EPMC8026061","cross_references":{"pubmed":["33826651"],"doi":["10.1371/journal.pone.0249791"]}}